Impact of Tiotropium Add-on Therapy in Patients With Asthma

Completed

Conditions studied: Asthma

In brief

To evaluate the effectiveness of add on therapy with Tiotropium Respimat® compared to increasing the dose of ICS in patients with a diagnosis of Asthma and on ICS/LABA therapy

Key facts

Study ID

NCT03964220

Run by

Boehringer Ingelheim

People needed

7857

Starts

2019-03-15

Expected to finish

2019-09-20

Last updated by the study team

2020-11-03

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with least one asthma diagnosis in the inpatient setting or at least two separate instances of asthma diagnosis (separated by at least 30 days) recorded in the outpatient or emergency room setting will be included.
• Patients will be required to be already on Inhaled Corticosteroid/Long-acting beta-agonist (ICS/LABA).
• Patients will be required to have available records 12 months prior to the index date.

You may not qualify if…

• Patients below the age of 6 years on the Inhaled Corticosteroid/Long-acting beta-agonist initiation (ICS/LABAi) date will be excluded.
• Patients with a diagnosis of COPD at any time during the study period will be excluded.
• Those who are on biologics at baseline will be removed.
• After the PSM process, unmatched patients will be excluded.

Where it is running

• eMax Health — White Plains, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.